Primary lung adenocarcinomas in children and adolescents treated for pediatric malignancies Journal Article


Authors: Kayton, M. L.; He, M.; Zakowski, M. F.; Moreira, A. L.; Lau, C.; Chou, A. J.; Merchant, M.; Merola, P. R.; Wexler, L. H.; La Quaglia, M. P.; Travis, W. D.; Ladanyi, M.
Article Title: Primary lung adenocarcinomas in children and adolescents treated for pediatric malignancies
Abstract: Introduction: Primary lung adenocarcinoma is extremely rare in the pediatric age group. There have been anecdotal reports of lesions that are histologically indistinguishable from adult-type pulmonary adenocarcinoma in young patients after treatment for nonpulmonary cancers. Herein, we present clinical, histopathologic, and molecular data on eight such cases. Methods: Histopathologic evaluation of the tumors was performed according to the World Health Organization classification. Molecular studies for EGFR and KRAS mutations were performed on six patients with sufficient material. Results: All eight patients were never smokers, four males and four females. Median age at nonpulmonary cancer diagnosis was 14 years (range, 3-23 years). Pulmonary adenocarcinomas were diagnosed at a median age of 15 years (range, 10-24 years); tumors were 0.1 to 2.0 cm in size and in some cases coexisted with metastases from the original cancer. Retrospective review showed that in at least three patients, the nodules were radiographically present before chemotherapy. Of six patients whose tumors were tested for common EGFR and KRAS mutations, two were positive for the former and one for the latter. At a median follow-up of 11 months (range, 2-29 months), six patients remained well without lung nodules and two had additional small, peripheral lung nodules that have not been biopsied. Conclusions: Pulmonary lesions found in young patients with pediatric cancers can be histologically indistinguishable from lung adenocarcinoma seen in adults, may display typical adenocarcinoma-associated mutations of EGFR and KRAS, and may precede the administration of cytotoxic chemotherapy. © 2010 by the International Association for the Study of Lung Cancer.
Keywords: osteosarcoma; adolescent; adult; cancer chemotherapy; child; clinical article; human tissue; school child; bone neoplasms; child, preschool; survival rate; retrospective studies; young adult; gene mutation; gene deletion; mutation; proto-oncogene proteins; disease course; histopathology; cancer recurrence; cisplatin; doxorubicin; cancer radiotherapy; combined modality therapy; methotrexate; topotecan; drug megadose; follow up; follow-up studies; neoplasm staging; adenocarcinoma; carboplatin; vasculotropin receptor; metastasis; computer assisted tomography; tumor volume; embryo; etoposide; thoracotomy; lung neoplasms; lung cancer; cyclophosphamide; vincristine; receptor, epidermal growth factor; ifosfamide; childhood cancer; sarcoma; lung adenocarcinoma; clinical study; neuroblastoma; dactinomycin; radiography; lung alveolus cell carcinoma; neoplasm invasiveness; neoplasms, second primary; ras proteins; egfr; kras; k ras protein; chondrosarcoma; nephroblastoma; lung lesion; lung nodule; bronchioloalveolar carcinoma; pamidronic acid; secondary malignancies; chondroblastoma; osteoblastoma; peripheral lung lesion; wilms tumor
Journal Title: Journal of Thoracic Oncology
Volume: 5
Issue: 11
ISSN: 1556-0864
Publisher: Elsevier Inc.  
Date Published: 2010-11-01
Start Page: 1764
End Page: 1771
Language: English
DOI: 10.1097/JTO.0b013e3181f69f08
PUBMED: 20975376
PROVIDER: scopus
PMCID: PMC4243865
DOI/URL:
Notes: --- - "Export Date: 20 April 2011" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Leonard H Wexler
    191 Wexler
  2. Andre L Moreira
    176 Moreira
  3. Alexander Ja-Ho Chou
    58 Chou
  4. Mark Lawrence Kayton
    19 Kayton
  5. Marc Ladanyi
    1326 Ladanyi
  6. Chyau-Yueh Christopher Lau
    20 Lau
  7. William D Travis
    743 Travis
  8. Maureen F Zakowski
    289 Zakowski
  9. Pamela Merola
    11 Merola
  10. Mai He
    6 He